Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.36) by 28.85 percent. This is a 475 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $52.59 million which missed the analyst consensus estimate of $54.60 million by 3.68 percent. This is a 4.19 percent increase over sales of $50.47 million the same period last year.